Menu Back to Event-Details

Realising the Potential of Future Biomedical Innovation: The Role of Intensified EU Cooperation on HTA

Track:
DIAmond Sessions

Day & Time:
April 17, 2:00PM - 3:30PM (Central Europe Standard Time)

Session Number:
DMD3

Type:
Session

Title:
Realising the Potential of Future Biomedical Innovation: The Role of Intensified EU Cooperation on HTA

Chair(s):
Timothy Wilsdon, MS
Principal
Charles River Associates International, United Kingdom

Description:
In light of the evolving medicine development paradigm and the limited resources of national HTA agencies it becomes increasingly apparent that the currently national and sub-national approach to the assessment of relative clinical efficacy of medicines will unlikely allow EU patients to optimally realize the potential benefits of the evolving drug development paradigm and future biomedical innovation. More recently the EMA and EUnetHTA have proposed a new framework for parallel early scientific advice which will be tested and further refined as part of the temporarily funded EUnetHTA JA3 programme. This development represents considerable progress, but the question remains how to increase efficiency and depth in the assessment of the relative clinical efficacy of innovative medicines at and after launch. Participants of this panel will present their perspectives on how to further advance the EU cooperation between national HTA agencies, EMA and other stakeholders on the assessment of the relative efficacy of medicines.

Presentation(s) & Speaker(s):
Panel Discussion
Ansgard Hebborn
Head – Global Market Access Policy
F. Hoffman-La Roche, Switzerland

Panel Discussion
Ioana-Raluca Siska
Policy Officer, Health Technology Assessment
European Commission, Belgium

Panel Discussion
Michael Berntgen, PhD
Head of Product Development Scientific Support Department
European Medicines Agency, European Union, United Kingdom